Trump unveils drug price deal with AstraZeneca

Axios – Friday, October 10, 2025
By Adriel Bettelheim and Peter Sullivan

President Trump and pharma giant AstraZeneca on Friday announced a deal to lower drug prices that largely tracks with a pact the White House struck with Pfizer last week.

Why it matters: It’s a continuation of drug industry efforts to avoid tariffs or onerous new regulations without taking a big hit to profits.

Driving the news: Astra Zeneca committed to Trump’s “most-favored nation” pricing for Medicaid and for newly launched drugs in the future, meaning the lowest price the drug sells for in other wealthy countries.

• The company will also sell discounted drugs on the new government-run TrumpRx website, for consumers who choose to buy directly without using insurance.
• AstraZeneca also on Thursday announced it was investing $4.5 billion in a new manufacturing plant near Charlottesville, Va., part of $50 billion commitment in U.S. manufacturing and R&D.
• Under the agreement, the company said it will get a three-year exemption from tariffs.

Yes, but: The AstraZeneca deal, like the previous Pfizer deal, does not directly lower existing prices in Medicare or private health insurance, where most Americans get their coverage.

• Some details of both deals are also still unclear, making it hard to accurately evaluate.

What they’re saying: “Nobody ever thought they were gonna see [these prices].. and don’t let Democrats take the credit,” Trump said in an Oval Office press conference, alongside AstraZeneca CEO Pascal Soriot.

What’s next: Other large drug companies are expected to reach similar deals in the coming weeks.

Access this article at its original source.